Wedge Capital Management Increases Stake in AbbVie

Summary

Wedge Capital Management L L P NC increased its stake in AbbVie Inc. (NYSE:ABBV) by 3.6% in Q2, acquiring an additional 5,666 shares, bringing its total to 164,792 shares valued at $30.59 million. Other institutional investors also adjusted their positions in AbbVie. Analysts have given AbbVie an average rating of ‘Moderate Buy’ with a target price of $222.68. AbbVie reported Q2 earnings of $2.97 EPS, missing estimates, but revenue increased by 6.6% year-over-year. The company announced a quarterly dividend of $1.64, payable on November 14.Market Beat

Impact Analysis

So basically, Wedge Capital Management’s move to increase its stake in AbbVie by 3.6% is a vote of confidence in the company’s long-term prospects, despite the recent earnings miss. The interesting part isn’t just the increase itself, but the timing—right after AbbVie’s Q2 earnings report showed a revenue increase of 6.6% year-over-year, even though EPS missed estimates.Market Beat This suggests that Wedge sees potential in AbbVie’s strategic moves, like its acquisition of Gilgamesh Pharmaceuticals for CNS treatments, which could unlock new revenue streams. The market might be underestimating AbbVie’s growth potential, especially with its strong patent position for RINVOQ until 2037. The technical analysis also supports a bullish outlook, with MACD and RSI indicators showing strength. I’d read this as a signal to consider AbbVie for a long-term position, especially if the stock dips near support levels.